company background image
0QLR logo

Novartis LSE:0QLR Stock Report

Last Price

CHF 87.95

Market Cap

CHF 176.1b

7D

-2.5%

1Y

3.7%

Updated

13 Dec, 2024

Data

Company Financials +

0QLR Stock Overview

Engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More details

0QLR fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health4/6
Dividends5/6

Novartis AG Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novartis
Historical stock prices
Current Share PriceCHF 87.95
52 Week HighCHF 115.98
52 Week LowCHF 83.61
Beta0.51
1 Month Change-4.36%
3 Month Change-10.32%
1 Year Change3.72%
3 Year Change10.21%
5 Year Change-5.10%
Change since IPO22.11%

Recent News & Updates

Recent updates

Shareholder Returns

0QLRGB PharmaceuticalsGB Market
7D-2.5%-0.5%-0.4%
1Y3.7%-1.6%6.2%

Return vs Industry: 0QLR exceeded the UK Pharmaceuticals industry which returned -1.6% over the past year.

Return vs Market: 0QLR underperformed the UK Market which returned 6.2% over the past year.

Price Volatility

Is 0QLR's price volatile compared to industry and market?
0QLR volatility
0QLR Average Weekly Movement2.1%
Pharmaceuticals Industry Average Movement6.3%
Market Average Movement4.9%
10% most volatile stocks in GB Market10.6%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0QLR has not had significant price volatility in the past 3 months compared to the UK market.

Volatility Over Time: 0QLR's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199676,057Vas Narasimhanwww.novartis.com

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors.

Novartis AG Fundamentals Summary

How do Novartis's earnings and revenue compare to its market cap?
0QLR fundamental statistics
Market capCHF 176.06b
Earnings (TTM)CHF 10.51b
Revenue (TTM)CHF 44.64b

16.7x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0QLR income statement (TTM)
RevenueUS$49.94b
Cost of RevenueUS$12.07b
Gross ProfitUS$37.87b
Other ExpensesUS$26.11b
EarningsUS$11.76b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 31, 2025

Earnings per share (EPS)5.88
Gross Margin75.83%
Net Profit Margin23.55%
Debt/Equity Ratio69.8%

How did 0QLR perform over the long term?

See historical performance and comparison

Dividends

3.7%

Current Dividend Yield

68%

Payout Ratio